Interestingly, there are ongoing clinical trials directed to targeting these genes, such as NCT03829436 studying the anti-tumor activity of TPST-1120, a selective antagonist of PPARα, in subjects with advanced solid tumors, and a phase I/II clinical trial using AZD3965, an MCT1 inhibitor, currently being evaluated in PCa [50]. Here, PPARA is linked to posterior cortical atrophy.